According to the latest report by IMARC Group, titled “Insomnia Market Report by Therapy Type (Non-Pharmacological Therapy, Pharmacological Therapy), Drug Class (Antidepressants, Melatonin Antagonist, Benzodiazepines, Nonbenzodiazepines, Orexin Antagonist, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies), and Region 2025-2033”, the global insomnia market size reached USD 5.3 Billion in 2024. Insomnia is a sleep disorder that affects a person's ability to fall asleep, stay asleep, or a combination of both. The condition of insomnia can be caused by another medical condition, or it can represent a symptom of a different medical condition. Symptoms of insomnia include difficulty falling asleep, staying asleep, waking up too early, or feeling unrefreshed after sleeping, as well as fatigue, irritability, and difficulty concentrating. This can lead to a variety of health problems, including depression and impaired cognitive function. There can be acute insomnia or chronic insomnia, characterized by episodes lasting a few days or weeks and chronic insomnia lasting a month or more. The causes of insomnia can range from medical conditions to lifestyle factors to psychological factors. In addition to behavioral therapy, medication, and lifestyle changes, insomnia can be managed with various treatments.
Global Insomnia Market Trends:
The global market is majorly driven by the growing prevalence of sleep disorders due to work-related stress, anxiety, and lifestyle changes among the masses. In line with this, a considerable rise in shift work and travel jet lag leading to the development of specific treatment options for these conditions is propelling the market growth. Moreover, the growing awareness regarding the negative impact of insomnia on productivity, health, and overall quality of life among the masses have augmented the demand for insomnia treatment options. In addition to this, continual technological advancements in treatment, such as wearable sleep trackers, online cognitive behavioral therapy, and other digital health solutions to facilitate easy access and sleep pattern monitoring, are leading to a higher uptake of insomnia diagnostics and therapeutics. The market is further driven by the easy availability of effective insomnia medications across online and offline organized pharmacy retail channels. Apart from this, the increasing geriatric population that is more susceptible to chronic insomnia and sleep disorders is creating a positive outlook for the market. Furthermore, the rising mental health awareness among the masses is resulting in a higher recognition of insomnia as a co-morbid condition, thereby fueling the market growth. Some of the other factors contributing to the market include the increasing hectic lifestyle of the masses, rising prevalence of numerous mental illnesses, growing medical expenditure, and extensive research and development (R&D) activities conducted by key players. On account of the aforementioned factors, the market is anticipated to reach a value of USD 6.8 Billion by 2033, exhibiting a CAGR of 2.55% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Therapy Type, Drug Class, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Astellas Pharma Inc., Aurobindo Pharma Limited, Biocodex, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Merck & Co. Inc., Neurim Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.), Takeda Pharmaceutical Company Limited and Vanda Pharmaceuticals Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800